GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:LIFE) » Definitions » Forward Dividend Yield %

aTyr Pharma (aTyr Pharma) Forward Dividend Yield % : 0.00% (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is aTyr Pharma Forward Dividend Yield %?

As of today (2024-04-25), the Forward Annual Dividend Yield of aTyr Pharma is 0.00%.

As of today (2024-04-25), the Trailing Annual Dividend Yield of aTyr Pharma is 0.00%.

LIFE's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.565
* Ranked among companies with meaningful Forward Dividend Yield % only.

aTyr Pharma's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of aTyr Pharma's Forward Dividend Yield %

For the Biotechnology subindustry, aTyr Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Forward Dividend Yield % falls into.



aTyr Pharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


aTyr Pharma  (NAS:LIFE) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


aTyr Pharma Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


aTyr Pharma (aTyr Pharma) Business Description

Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Executives
Sanjay Shukla officer: Chief Medical Officer C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Paul Schimmel director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jill Marie Broadfoot officer: Chief Financial Officer 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Sara Zaknoen director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke director C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Nancy Krueger officer: See Remarks C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Svetlana Lucas director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
John Mendlein director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p. 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah officer: Vice President, Manufacturing C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake officer: Vice President, Finance C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King officer: See Remarks 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121